Conditions: Sleep Initiation and Maintenance Disorders
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 24
Healthy volunteers: yes

Brief summary:
The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy Japanese participants. The study has four treatment periods. Participants will receive a single dose of LY2624803 or placebo in each treatment period.

Detailed description:

Arms:
arm 1: Single dose of 0.1 mg LY2624803 administered orally in up to 2 of 4 treatment periods arm 2: Single dose of 1.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods arm 3: Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods arm 4: Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods arm 5: Single dose of placebo administered orally in up to 1 of 4 treatment periods

Interventions: intervention 1: LY2624803 - Solution intervention 2: LY2624803 - Capsule intervention 3: Placebo - Solution intervention 4: Placebo - Capsule
Intervention descriptions: intervention 1: Administered orally as reconstituted solution intervention 2: Administered orally as a capsule intervention 3: Administered orally as solution intervention 4: Administered orally as a capsule

Protocol document: